Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Inventory: 2011-2024

Historic Inventory for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $170.2 million.

  • Adma Biologics' Inventory rose 14.47% to $196.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.7 million, marking a year-over-year increase of 14.47%. This contributed to the annual value of $170.2 million for FY2024, which is 1.54% down from last year.
  • As of FY2024, Adma Biologics' Inventory stood at $170.2 million, which was down 1.54% from $172.9 million recorded in FY2023.
  • Adma Biologics' Inventory's 5-year high stood at $172.9 million during FY2023, with a 5-year trough of $81.5 million in FY2020.
  • Its 3-year average for Inventory is $168.8 million, with a median of $170.2 million in 2024.
  • In the last 5 years, Adma Biologics' Inventory skyrocketed by 52.97% in 2021 and then declined by 1.54% in 2024.
  • Yearly analysis of 5 years shows Adma Biologics' Inventory stood at $81.5 million in 2020, then skyrocketed by 52.97% to $124.7 million in 2021, then skyrocketed by 30.91% to $163.3 million in 2022, then rose by 5.90% to $172.9 million in 2023, then declined by 1.54% to $170.2 million in 2024.